DOSS.COM | $18,000,000 | (Apr 16, 2025)
HepaRegeniX GmbH | $24,359,707 | (Apr 16, 2025)
Loti | $16,200,000 | (Apr 16, 2025)
PlateletBio
United States
- Watertown, Massachusetts
- 04/11/2021
- Series B
- $75,500,000
PlateletBio is the only allogeneic cell therapy company focused on platelet biology. We are pioneers, discovering a completely new category in therapeutics. Our approach is one-of-a-kind, recreating nature’s legendary delivery cell. In doing so, we’re developing a superior cell therapy empowered to tackle previously unmet medical challenges.
- Industry Biotechnology Research
- Website https://www.plateletbio.com/
- LinkedIn https://www.linkedin.com/company/platelet-biogenesis/about/
Related People
Sam RastyFounder
United States -
Greater Boston
Biotech CEO with 25+ years of experience in leadership roles of increasing responsibility spanning global large pharma, mid-cap pharma and small, private biotech. Success in start-up company formation and launch, strategy formulation, fund raising, operations, R&D, manufacturing, corporate development, BD&L and M&A. Strategic and operational leader with product development experience in multiple therapeutic areas and technology platforms spanning small molecules to biologics to more complex gene and cell therapies.
Liminal(US) | $8,500,000 | (Apr 16, 2025)
TheStage AI | $4,500,000 | (Apr 16, 2025)
Homemove | $5,000,000 | (Apr 16, 2025)
Corvic AI | $12,000,000 | (Apr 16, 2025)
IUNU | $20,000,000 | (Apr 16, 2025)
Virtue AI | $30,000,000 | (Apr 16, 2025)
collide. | $5,000,000 | (Apr 16, 2025)
Friday Harbor | $6,000,000 | (Apr 16, 2025)
Mainspring Energy | $258,000,000 | (Apr 16, 2025)